Assay Detail
Functional
CHEMBL4024299
Review assay metadata, readout intent, target linkage, and publication context from the same page.
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
3
Total Activities
3
Compounds Tested
1
Activity Types
0
Assay Parameters
Assay Information
| Assay Type | Functional |
| Organism | Homo sapiens |
| Cell Type | HepG2 |
| Confidence | 1 — Organism |
| Curated By | Autocuration |
Publication
Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer.
Activity Statistics
| Type | Count | Avg pChEMBL | Best pChEMBL |
|---|---|---|---|
| IC50 | 3 | 5.53 | 5.59 |
Compounds Tested
| Compound | Name | Phase | Activities | Best pChEMBL |
|---|---|---|---|---|
| CHEMBL98 | VORINOSTAT | 4.0 | 1 | 5.59 |
| CHEMBL4063500 | — | — | 1 | 5.47 |
| CHEMBL3545110 | RIBOCICLIB | 4.0 | 1 | - |
Activity Data
| Compound | Name | Type | Rel. | Value | Units | pChEMBL |
|---|---|---|---|---|---|---|
| CHEMBL98 | VORINOSTAT | IC50 | = | 2570.0 | nM | 5.59 |
| CHEMBL4063500 | — | IC50 | = | 3370.0 | nM | 5.47 |
| CHEMBL3545110 | RIBOCICLIB | IC50 | > | 10000.0 | nM | - |